PepEvolutionLiraglutide
Saxenda / Victoza
The original once-daily GLP-1 — FDA-approved, strong cardiovascular data, but largely superseded by weekly semaglutide.
Verdict — B · Viable
Strong, well-replicated evidence and an established safety record, but daily dosing is inferior to weekly semaglutide and the gray-market supply carries the same counterfeit risks. A viable B-grade workhorse — obtain it through a licensed provider.
Overview
Liraglutide is a daily GLP-1 receptor agonist FDA-approved for obesity (Saxenda, 2014) and type-2 diabetes (Victoza, 2010), with robust RCT evidence including the SCALE program and the LEADER cardiovascular outcomes trial. It was the category standard before semaglutide, and while the science is strong, the daily injection burden and gray-market supply issues mirror the rest of the GLP-1 class.
PepScore Breakdown — the four axes
Evidence
35% weightHow strong is the published human science?
Sourcing & COA
30% weightOur moatCan a buyer obtain an independently-verified, high-purity version? — our proprietary layer.
Safety & Risk
25% weightWhat is the real-world harm potential?
Practicality
10% weightHow easy is it to actually run a verified version?
Sources & Citations
Every claim cites a primary source. Citations are machine-audited against NCBI — see methodology.
Educational only — not medical advice. PepScore is an educational research grade, not a prescription or dosing recommendation. Some vendor links are affiliate links — this never affects grades. Consult a licensed healthcare provider before using any compound.